Tiziano Barbui, MD
Ospedali Riuniti di Bergamo
Bergamo, Italy
Giovanni Barosi, MD
IRCCS Policlinico San Matteo
Pavia, Italy
John M. Bennett, MD
University of Rochester
Medical Center
Rochester, New York
Francisco Cervantes, MD
Hospital Clinic, University
of Barcelona
Barcelona, Spain
Richard E. Champlin, MD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas
Stefan Constantinescu, MD, PhD
Ludwig Institute for Cancer Research
Brussels, Belgium
Jorges Cortes, MD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas
Nick C.P. Cross, MA, PhD, FRCPath
University of Southampton
Salisbury, United Kingdom
Heinz Gisslinger, MD
Medical University of Vienna
Vienna, Austria
John Goldman, MD
Hammersmith Hospital
Imperial College London
London, United Kingdom
Anthony R. Green, PhD, FRCP, FRCPath
Cambridge Institute for Medical Research
Addenbrooke’s Hospital
Cambridge, United Kingdom
Rudiger Hehlmann, MD, PhD
Klinikum Mannheim der Universität
Heidelberg Mannheim
Mannheim, Germany
Ronald Hoffman, MD
Mount Sinai School of Medicine
New York, New York
Hagop M. Kantarjian, MD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas
Jean-Jacques Kiladjian, MD, PhD
Hopital Avicenne and Paris 13 University
Bobigny, France
Alan F. List, MD
H. Lee Moffitt Cancer Center
and Research Institute
Tampa, Florida
Ruben A. Mesa, MD
Mayo Clinic
Rochester, Minnesota
Vesna Najfeld, MD
Mount Sinai School of Medicine
New York, New York
Heike L. Pahl, PhD
University Hospital Freiburg
Freiburg, Germany
Josef T. Prchal, MD
University of Utah
Health Sciences Center
Salt Lake City, Utah
Jerry Radich, MD
Fred Hutchinson Cancer
Research Center
Seattle, Washington
Gail J. Roboz, MD
Weill Cornell Medical College
New York, New York
Damiano Rondelli, MD
University of Illinois at Chicago
Chicago, Illinois
Andrew I. Schafer, MD
Weill Cornell Medical College
New York, New York
Christopher B. Schaffer, PhD
Cornell University
New York, New York
Richard T. Silver, MD, FACP
Weill Cornell Medical College
New York, New York
Radek Skoda, MD
University Hospital Basel
Basel, Switzerland
Jerry L. Spivak, MD, FACP
Johns Hopkins University
Balimore, Maryland
Ayalew Tefferi, MD
Mayo Clinic
Rochester, Minnesota
William Vainchenker, MD, PhD
Institut Gustave Roussy
Villejuif, France
Irving Weissman, MD
Stanford School of Medicine
Stanford, California
Neal S. Young, MD
National Institutes of Health
Bethesda, Maryland
Thursday
November 5, 2009
8:00 am
Welcome and Introduction
Richard T. Silver, MD, FACP
Session I: Myelodysplastic Syndromes
Chairs: John M. Bennett, MD and Alan F. List, MD
8:30 am
Keynote Address: Normal and neoplastic stem cells
Irving Weissman, MD
9:30 am
Classification, morphology, and pathogenesis of myelodysplastic diseases
John M. Bennett, MD
10:00 am
The interface of aplastic anemia and MDS; treatment measures
Neal S. Young, MD
10:30 am Break
10:45 am
Current treatment developments & hypomethylator therapy in MDS
Alan F. List, MD
11:15 am
New drugs in MDS – Treatment of iron overload
Gail J. Roboz, MD
11:45 am
Which transplant and when for patients with MDS
Richard E. Champlin, MD
12:15 pm
Discussion / Questions
12:45 pm
Lunch
Session II: Myelofibrosis
Chairs: Ronald Hoffman, MD and Ayalew Tefferi, MD
1:30 pm
Allogeneic transplantation in primary myelofibrosis: Relevance of the new prognostic classification
Francisco Cervantes, MD
2:00 pm
Markers other than JAK2 and their significance
Heike L. Pahl, PhD
2:30 pm
Migration of hematopoetic stem cells and niche abnormalities
Ronald Hoffman, MD
3:00 pm
Novel therapies and assessing response in PMF
Ruben A. Mesa, MD
3:30 pm
Break
4:00 pm
Update on JAK2 inhibitors
Ayalew Tefferi, MD
4:30 pm
Clinical significance of endothelial lineage in progression and thrombosis
Giovanni Barosi, MD
5:00 pm
Panel discussion: Do we know enough to recommend transplantation for PM?
Chair: Francisco Cervantes, MD
Participants: Richard E. Champlin, M,D Ronald Hoffman, MD and Damiano Rondelli, MD
5:30 pm
Adjourn
Friday
November 6, 2009
Session III: Polycythemia Vera and Essential Thrombocythemia I
Chairs: Nick C.P. Cross, MA, PhD, FRCPath and Richard T. Silver, MD, FACP
8:30 am
Genetics of myeloproliferative disorders with emphasis on ET
Radek Skoda, MD
9:00 am
Germline and somatic mutations in PV: Clinical significance
Josef T. Prchal, MD
9:30 am
JAK2V6180F MPD: One or several genetic events?
William Vainchenker, MD, PhD
10:00 am
Break
10:30 am
Pegylated interferon in PV
Jean-Jacques Kiladjian, MD, PhD
11:00 am
Genotype and phenotype in chronic myeloproliferative disorders
Jerry L. Spivak, MD, FACP
11:30 am
Cerebral circulation in PV
Richard T. Silver, MD, FACP and Christopher B. Schaffer, PhD
12:00 pm
Lunch
Session IV: Polycythemia Vera and Essential Thrombocythemia II
Chairs: Andrew I. Schafer, MD and Jerry L. Spivak, MD, FACP
1:30 pm
Inherited and acquired genetic abnormalities in myeloproliferative disorders
Nick C.P. Cross, MA, PhD, FRCPath
2:00 pm
Molecular drug targets in myeloproliferative disorders
Stefan Constantinescu, MD, PhD
2:30 pm
The molecular pathogenesis of the myeloproliferative disorders - JAK2 goes nuclear
Anthony R. Green, PhD, FRCP, FRCPath
3:00 pm
Break
3:30 pm
Risk factors for thrombosis in MPDs
Tiziano Barbui, MD
4:00 pm
Update on clinical studies with anagrelide
Heinz Gisslinger, MD
4:30 pm
Selected abstract and poster review
Chair: Jerry L. Spivak, MD, FACP
Panel: Ruben A. Mesa, MD, Vesna Najfeld, PhD and Jerry L. Spivak, MD, FACP
5:15 pm
Adjourn
Saturday
November 7, 2009
Session V: Chronic Myeloid Leukemia (CML)
Chairs: John Goldman, DM, FRCP and Rudiger Hehlmann, MD, PhD
8:30 am
Update on biology and pathogenesis
John Goldman, DM, FRCP
9:00 am
Monitoring response to therapy/mechanisms of resistance
Jerry P. Radich, MD
9:30 am
“Conventional” therapy of CML, including management of pregnancy in CML
Hagop M. Kantarjian, MD
10:00 am
Break
10:30 am
Second and third generation tyrosine kinase inhibitors
Jorge Cortes, MD
11:00 am
Treatment of accelerated and blast phase disease update
Rudiger Hehlmann, MD, PhD
11:30 am
Phase III studies: International update
Speaker invited
12:00 pm
Role of transplantation in 2009
Richard E. Champlin, MD
12:30 pm
Discussion
1:00 pm
Adjourn
Participants interested in presenting data should submit abstracts online at www.imedex.com by August 18, 2009. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final course book and scheduled for oral or poster presentation.
Acceptance notifications and guidelines for poster presentations will be sent by September 15, 2009. Authors of accepted abstracts who have not registered will have until October 22, 2009 to do so at the rate of $325. After this date, abstracts without registered presenters will be disregarded.
Abstract Guidelines
- Follow the online instructions
- Abstracts must be written in English
- Accepted format: Word document format, 9 point Arial font,500 word count limit
- Use a concise title
- List affiliations of author(s) as briefl y as possible, with city, state and country
- Place an asterisk (*) before the name of the presenting author
- Use standard and well-accepted abbreviations
- When using references, use standard and well-accepted formats
- Abstract content should be single-spaced, typed in lower case
and contain:
- Purpose of the study
- Summarized description of the project
- Results and conclusions
Submission Deadline:
August 18, 2009
Submission Instructions:
Go to www.imedex.com, select this Congress and follow instructions in the "Abstracts" section.
Registration Fees
Discounted .....................................................$ 325
If payment received by September 1, 2009
Regular ..........................................................$ 425
If payment received by October 29, 2009
Full/Onsite ....................................................$ 525
If payment received after October 29, 2009
Group discount (physicians only)* ...............-$ 50
*cannot be combined with any other discounts
Nurses/Residents/Students* ..........................$ 199
*proof of eligibility must accompany registration *cannot be combined with any other discounts
To Register: You may register online by October 29,2009 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available to Nurses/Residents/Students.
Payment: To pre-register, registration and payment must be received no later than October 29, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than October 29, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 29, 2009.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
New York Marriott at the Brooklyn Bridge
333 Adams Street Brooklyn, New York 11201,
USA Tel.: +1 (718) 246 7000
Fax: +1 (718) 246 0563
www.brooklynmarriott.com
Located in New York City’s most celebrated neighborhood, just across the river from Manhattan sits the New York Marriott at the Brooklyn Bridge. Fresh from a 2007 expansion and renovation, the hotel boasts a relaxed but modern atmosphere with state-of-the-art amenities. The hotel sits within Renaissance Plaza, adjacent to the Metro Tech Center and surrounding universities and is a short 5 minutes from Manhattan and the Financial District, with 9 major subway lines all within one block.
For the convenience of attendees, a limited number of rooms have been reserved until October 14, 2009 at a discounted rate of $ 299 single/double occupancy, plus tax New York State tax (8.375%), New York City tax (5%) and occupancy tax ($3.50) per night. This rate is not guaranteed outside the congress dates or after October 14, 2009.
To reserve your room please contact New York Marriott at the Brooklyn Bridge reservations department at (888) 436 3759 or (718) 246 7000. To receive the group rate, callers must identify themselves as being with the International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. Reservation requests received after October 14, 2009 may not be guaranteed the group rate.
Chair and Convener:
Richard T. Silver, MD, FACP
Weill Cornell Medical College
New York, New York
Co-Chair:
Jerry L. Spivak, MD, FACP
Johns Hopkins University
Baltimore, Maryland
Dear Colleague,
It is our pleasure to invite you to join us at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. The 2009 Congress, which will be held November 5-7 at the New York Marriott at the Brooklyn Bridge, promises to be our most exciting and interactive meeting yet!
Since the inaugural Congress in 2001, this meeting has grown to nearly 600 attendees and has become the premier forum for discussion on the latest advances in myeloproliferative diseases and myelodysplastic syndromes. It allows attendees a forum to update their knowledge in the field, confirm their current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options.
Guided by the expertise of the leaders in the fi elds of molecular biology, pathology, immunology, and translational and clinical research, this Congress promises to be a stimulating, interactive forum for attendees from all relevant medical specialties. We will focus on the most recent updates and debates centered around polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukemia and myelodysplasia.
With its diverse mix of oncologists, hematologists, surgeons, and pathologists, this will be a great place to interact with your colleagues and learn from internationally renowned faculty.
We look forward to welcoming you in November to New York as the Fall brings its special beauty to this exciting international city!
Sincerely,
Richard T. Silver, MD, FACP
Chair and Convener
Jerry L. Spivak, MD, FACP
Co-Chair
ORGANIZER
Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2008 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
The following companies have provided an educational grant in support of this Congress:
SILVER
BRONZE
CORPORATE
Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.
The following companies are exhibitors at this congress:
Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712, or by email at c.gunter@imedex.com.
